Shares of Mazor Robotics Ltd – (NASDAQ:MZOR) were up 4.9% on Thursday . The company traded as high as $23.64 and last traded at $23.45, with a volume of 139,806 shares. The stock had previously closed at $22.35.

A number of analysts have weighed in on MZOR shares. Zacks Investment Research upgraded Mazor Robotics Ltd – from a “sell” rating to a “hold” rating in a report on Thursday, May 19th. Needham & Company LLC restated a “hold” rating on shares of Mazor Robotics Ltd – in a report on Tuesday, May 10th. Standpoint Research started coverage on Mazor Robotics Ltd – in a report on Friday, July 8th. They set a “buy” rating and a $30.00 target price for the company. Barclays PLC upped their target price on Mazor Robotics Ltd – from $16.00 to $23.00 and gave the stock an “overweight” rating in a report on Thursday, July 14th. Finally, Sterne Agee CRT lowered Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a report on Tuesday, May 31st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Mazor Robotics Ltd – currently has an average rating of “Buy” and an average target price of $25.00.

The firm’s market capitalization is $508.88 million. The company’s 50 day moving average is $21.07 and its 200 day moving average is $14.52.

Mazor Robotics Ltd – (NASDAQ:MZOR) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $8.51 million. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.05) EPS. Equities research analysts expect that Mazor Robotics Ltd – will post ($0.63) earnings per share for the current year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.